Publication | Closed Access

Phase I Study of the BLP25 (MUC1 Peptide) Liposomal Vaccine for Active Specific Immunotherapy in Stage IIIB/IV Non–Small-Cell Lung Cancer

Muc1 PeptideTumor ImmunologyMedicineLiposomal VaccineImmunologyTherapeutic VaccineImmune SurveillanceImmune Checkpoint InhibitorT Cell ImmunityImmunotherapeuticsActive Specific ImmunotherapyImmunotherapyOncologyRadiation OncologyLung Cancer